featured
Early Postnatal High-Dose Fat-Soluble Enteral Vitamin A Supplementation to Lower Risk for Moderate or Severe Bronchopulmonary Dysplasia or Death in Infants With Extremely Low Birthweight
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial
Lancet Respir Med 2024 Apr 18;[EPub Ahead of Print], S Meyer, J Bay, AR Franz, H Erhardt, L Klein, J Petzinger, C Binder, S Kirschenhofer, A Stein, B Hüning, A Heep, E Cloppenburg, J Muyimbwa, T Ott, J Sandkötter, N Teig, S Wiegand, M Schroth, A Kick, D Wurm, C Gebauer, K Linnemann, J Kittel, C Wieg, U Kiechl-Kohlendorfer, S Schmidt, R Böttger, W Thomas, F Brevis Nunez, A Stockmann, T Kriebel, A Müller, D Klotz, P Morhart, D Nohr, HK Biesalski, EZ Giannopoulou, S Hilt, M Poryo, S Wagenpfeil, N Haiden, C Ruckes, A Ehrlich, L GortnerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.